Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
Provided By Globe Newswire
Last update: Nov 10, 2022
- Shifted Focus to SIVEXTRO to Enable Cost Cutting -
- Cash Runway Extended into Q1 2023 -
- Q3 2022 Total Revenue of $9.2 Million -
Read more at globenewswire.com
